Step Two For Ilaris: Advisory Panel To Consider Whether To Add Gout Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
The biologic is the product of a Novartis strategy to test proof-of-concept early on; Phase III data look at time to first flare and pain intensity.
You may also be interested in...
NIBR Model Improves Novartis Early Pipeline Success Rate
Eight years after Novartis AG launched the Novartis Institutes for Biomedical Research under Harvard Medical School cardiologist Mark Fishman and let him design a novel strategy for vetting early-stage projects, the company's Phase II success rate for new molecular entities has doubled.
Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned
Development portfolio for interleukin-1ß blocker is sign of success for Novartis proof of concept R&D development model.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.